sr 48692 has been researched along with sq 109 in 1 studies
| Studies (sr 48692) | Trials (sr 48692) | Recent Studies (post-2010) (sr 48692) | Studies (sq 109) | Trials (sq 109) | Recent Studies (post-2010) (sq 109) |
|---|---|---|---|---|---|
| 203 | 3 | 36 | 58 | 3 | 41 |
| Protein | Taxonomy | sr 48692 (IC50) | sq 109 (IC50) |
|---|---|---|---|
| Geranylgeranyl pyrophosphate synthase | Homo sapiens (human) | 4.5 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 5.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Codd, R; Liao, V; Lifa, T; Liu, J; Obando, D | 1 |
1 review(s) available for sr 48692 and sq 109
| Article | Year |
|---|---|
The many faces of the adamantyl group in drug design.
Topics: Adamantane; Animals; Antimalarials; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Iron Chelating Agents; Iron Overload; Malaria; Solubility | 2011 |